September 19, 2017

The Honorable Paul Ryan
Speaker
U.S. House of Representatives
Washington, D.C. 20510

The Honorable Nancy Pelosi
Democratic Leader
U.S. House of Representatives
Washington, D.C. 20510

Dear Speaker Ryan and Democratic Leader Pelosi:

As the Senate returns to work this Fall, the undersigned organizations encourage the House to consider the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. Our organizations represent a broad-based and diverse cross-section of stakeholders – including providers and payers, physicians and consumers, corporations and unions – all of whom have come together in strong support of the CREATES Act.

For too long, brand-name pharmaceutical manufacturers have exploited patient safety tools in order to stifle generic competition and attendant lower prescription drug prices. The Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently testified on this topic at a hearing in front of the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law:

For example, we know that sometimes statutory and regulatory requirements, established to ensure the safety and quality of drugs approved by FDA, may also be leveraged – or “gamed” – in an effort to delay generic drug approvals beyond the timeframe the law has intended. This can serve to thwart expected competition.

This “gaming” by brand-name pharmaceutical companies denies generic manufacturers access to the samples that they require in order to conduct necessary equivalence testing to ensure the quality, efficacy, and safety of a generic drug. As a result of this pattern of anticompetitive practices, brand-name manufacturers are able to stifle generic competition, inflating prescription drug prices by artificially extending their monopoly pricing power far beyond the exclusivity period intended by Congress.

This anticompetitive conduct harms not only the patients who depend on these drugs, but results in an enormous and unnecessary burden on the healthcare system as a whole. A 2014 study by Matrix Global Advisors found that this type of anticompetitive conduct costs the healthcare system $5.4 billion annually, including $1.8 billion in government spending and nearly $1 billion in out-of-pocket costs for patients.

The CREATES Act is a targeted, market-based, bipartisan solution to this longstanding problem that affects both access to and affordability of prescription medications. We thank the bipartisan, bicameral Congressional sponsors of this legislation, as well as the Food and Drug Administration and the Federal Trade Commission which recently testified favorably about this bill.
We strongly encourage Congress to act on this important bill this fall, and we stand ready to work with Members towards our common goal of promoting competition and lowering drug prices for all Americans.

Sincerely,

AARP
AFL-CIO
American College of Physicians
Anthem
Alliance of Community Health Plans
American Hospital Association
American Society of Health System Pharmacists
America’s Health Insurance Plans
Ascension
Blue Cross Blue Shield Association
Blue Cross Blue Shield of Arizona
Blue Cross Blue Shield of Michigan
Blue Shield of California
Campaign for Sustainable Rx Pricing
Center for Medicare Advocacy
Coalition to Reduce Spending
CVS Health
Doctors for America
Families USA
Federation of American Hospitals
Freedom Works
Greater New York Hospital Association
Healthcare Supply Chain Association
Kaiser Permanente
Knowledge Ecology International
National Center for Health Research
National Committee to Preserve Social Security and Medicare
National Physicians Alliance
Patients for Affordable Drugs
Pharmaceutical Care Management Association
Prime Therapeutics
Public Citizen
Social Security Works
Treatment Action Group
Vizient
Walmart

Cc: Chairman Robert W. Goodlatte
Cc: Ranking Member John Conyers
Cc: Representative Tom Marino
Cc: Representative David Cicilline